Multivariate analysis demonstrated that elevated CRP/MCV ratio [odds ratio (OR): 1.535, 95% CI: 1.121–2.104, P = 0.008], TNM stage (OR: 2.747, 95% CI: 2.175–3.469, P < 0.001), and differentiation (OR, 1.384; 95% CI, 1.150–1.666; P = 0.001) were significant predictors of overall survival in patients with CRC (Figure 2). This evidence concerns the gene CRP and colorectal carcinoma.